nArgBP2 Inhibitors
Chemical inhibitors of nArgBP2 operate through interference with the phosphorylation processes of proteins within signaling pathways that nArgBP2 is involved in. Lithium Chloride, SB216763, Indirubin-3'-monoxime, and TDZD-8 are chemicals that inhibit the enzyme GSK-3β. The inhibition of GSK-3β leads to a reduction in the phosphorylation of substrates within the GSK-3β signaling pathways. Since nArgBP2 interacts with proteins that are substrates for GSK-3β, its ability to bind to its target proteins is reduced when these substrates are less phosphorylated. SB216763, Indirubin-3'-monoxime, CHIR99021, and AR-A014418 specifically prevent the phosphorylation of these proteins, thereby affecting nArgBP2's functionality. TDZD-8 stands out as a non-ATP competitive GSK-3β inhibitor, which suggests a unique mode of action in reducing nArgBP2 activity by altering the phosphorylation state of the involved proteins without competing at the ATP binding site.
On the other hand, Paullones, Roscovitine, Purvalanol A, Olomoucine, Kenpaullone, and Alsterpaullone focus on inhibiting cyclin-dependent kinases (CDKs), which also play a role in the regulation of nArgBP2. nArgBP2 is known to interact with CDK5, a member of the CDK family. The inhibitors Paullones, Roscovitine, and Olomoucine selectively target CDKs, which leads to a change in the phosphorylation pattern of nArgBP2-associated proteins. Kenpaullone and Alsterpaullone exhibit a dual inhibition effect on both GSK-3β and CDKs, suggesting they can affect nArgBP2 activity by multiple pathways. By altering the phosphorylation status of proteins within the GSK-3β and CDK5 pathways, these inhibitors can reduce the functional activity of nArgBP2 through a broad spectrum of action.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium Chloride can inhibit the GSK-3β enzyme. Since nArgBP2 is known to interact with proteins that are substrates for GSK-3β, inhibition of GSK-3β by Lithium Chloride can reduce phosphorylation of these substrates, thus potentially reducing nArgBP2's ability to bind to its target proteins. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
SB216763 acts as a GSK-3β inhibitor. By inhibiting GSK-3β, SB216763 prevents the phosphorylation of proteins within the GSK-3β signaling pathway, which is a pathway that nArgBP2 is involved in through its protein-protein interactions, leading to a decrease in nArgBP2's functional activity. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
As an inhibitor of GSK-3β, Indirubin-3'-monoxime prevents the phosphorylation of proteins that interact with nArgBP2. This chemical effectively reduces nArgBP2's binding to its partners, thereby inhibiting its function. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine selectively inhibits CDKs, including CDK5. By inhibiting CDK5, it would affect the phosphorylation state of proteins that nArgBP2 may associate with, thereby inhibiting the function of nArgBP2. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A is another CDK inhibitor that would lead to changes in the phosphorylation status of proteins that are part of the pathway in which nArgBP2 functions, resulting in an inhibition of nArgBP2's activity. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is a CDK inhibitor, and its action could potentially inhibit nArgBP2 by altering the phosphorylation patterns of proteins within the CDK5 pathway, which is a pathway nArgBP2 is associated with. | ||||||
Kenpaullone | 142273-20-9 | sc-200643 sc-200643A sc-200643B sc-200643C | 1 mg 5 mg 10 mg 25 mg | $61.00 $153.00 $231.00 $505.00 | 1 | |
Kenpaullone, by inhibiting GSK-3β and CDKs, could inhibit nArgBP2 by changing the phosphorylation state of proteins that interact with nArgBP2, thus inhibiting its function. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone inhibits CDKs and GSK-3β, possibly leading to decreased functional activity of nArgBP2 due to changes in the phosphorylation state of proteins in pathways where nArgBP2 is involved. | ||||||
GSK-3β Inhibitor VIII | 487021-52-3 | sc-202636 sc-202636A | 5 mg 10 mg | $134.00 $150.00 | 5 | |
AR-A014418 is a selective GSK-3β inhibitor. It may inhibit nArgBP2 function by interfering with the GSK-3β pathway and its associated proteins, which are necessary for nArgBP2's activity. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
CHIR99021 is a potent GSK-3β inhibitor. It could inhibit nArgBP2 by altering the phosphorylation pattern of the proteins within the GSK-3β signaling pathway, thereby impacting nArgBP2's activity. | ||||||